--- title: "2026 年應該在哪裏進行投資？PL Capital 的專家為您解讀最佳投資選擇" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/282945069.md" description: "在最近的一場網絡研討會上，券商 Prabhudas Lilladher（PL Capital）建議投資者在全球緊張局勢影響市場的情況下保持謹慎但又要抓住機會。專家強調關注結構性主題和高信念投資的重要性，特別是在物流、乙醇和醫療保健等行業。他們指出，儘管印度表現出韌性，但原油價格上漲可能會影響通脹和增長預期。市場目前處於區間震盪狀態，需要在投資策略上保持精準，雙重關注防禦性行業和週期性復甦機會。總體而言，信息強調質量重於數量，以及選擇性參與特定行業" datetime: "2026-04-15T21:50:33.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/282945069.md) - [en](https://longbridge.com/en/news/282945069.md) - [zh-HK](https://longbridge.com/zh-HK/news/282945069.md) --- # 2026 年應該在哪裏進行投資？PL Capital 的專家為您解讀最佳投資選擇 In a market shaped by global tensions and shifting sector dynamics, brokerage firm Prabhudas Lilladher (PL Capital) is advising investors to stay grounded—but not passive. At its recent PL Alpha: India View webinar, the firm brought together senior research and advisory voices to decode what lies ahead for Indian equities. The message was clear: brace for volatility, but don’t lose sight of India’s structural strength. According to Amnish Aggarwal, Co-Head – Institutional Equities, the past few weeks have been marked by sharp swings, largely driven by rising geopolitical tensions involving the US, Israel, and Iran. Yet, India has held up relatively well. Policy interventions—such as cuts in oil taxes—have helped cushion immediate shocks. But Aggarwal cautioned that the real impact may still be building beneath the surface. Higher crude prices could trigger second-order effects, pushing inflation higher in the coming months and potentially forcing a reset in growth and earnings expectations. For investors, that means one thing: don’t confuse short-term stability with long-term immunity. **Advisory view: Focus on structural themes and stock opportunities: Vikram Kasat, Vikram Kasat (Head –Advisory)** From an advisory standpoint, Vikram Kasat, Head – Advisory, highlighted a shift in how capital is being deployed. Instead of broad-based bets, investors—especially HNIs and institutions—are gravitating toward high-conviction, theme-driven opportunities. **Key sectors in focus include:** - Logistics, powered by e-commerce growth - Ethanol, backed by government blending policies - Healthcare, offering defensive stability At the same time, newer-age themes are gaining traction: - Artificial intelligence - Robotics - Specialized manufacturing This signals a deeper transition in markets—from cyclical chasing to structural investing. **Markets in a Holding Pattern** On the technical side, the outlook is more measured. Vaishali Parekh (Technical Research) and Shilpa Rout (Derivatives Research) pointed to a range-bound market, with indices like Nifty moving within a wide band as investors wait for clearer triggers. - Defined support and resistance levels are in play - Momentum is selective, not broad-based **Sectorally:** Metals, banks, and autos are showing strength Textiles and chemicals may be nearing a turnaround phase In other words, this isn’t a market for blanket bets—it’s a market for precision. **Sectoral strategy: Defensive resilience and cyclical recovery plays** Throughout the deliberations, the following two-pronged investment strategy emerged as key: Defensive posture in industries like pharmaceuticals and utilities during uncertain times Cyclical play in capital goods, metals, cement, and engineering, especially in case of de-escalation in geopolitics Capital goods, defense, and infra-related sectors remain strong structural growth bets. **Cautious optimism amid uncertainty** It is important to be careful of international events that may affect issues like inflation, fiscal deficits, and profit margins through their spill-over effects. However, despite some hitches encountered during the discussion, the experts managed to communicate critical aspects of their strategies effectively. **PL Capital’s core message to investors is nuanced but actionable:** Stay cautious, because global risks—from inflation to fiscal pressures—are real Stay opportunistic, because India’s macro fundamentals remain strong The current market isn’t about aggressive risk-taking or complete withdrawal. It’s about: - Choosing quality over quantity - Maintaining diversification - Being selective with sectors and themes ### 相關股票 - [BBH.US](https://longbridge.com/zh-HK/quote/BBH.US.md) - [159615.CN](https://longbridge.com/zh-HK/quote/159615.CN.md) - [588130.CN](https://longbridge.com/zh-HK/quote/588130.CN.md) - [INDA.US](https://longbridge.com/zh-HK/quote/INDA.US.md) - [AVEM.US](https://longbridge.com/zh-HK/quote/AVEM.US.md) - [VHT.US](https://longbridge.com/zh-HK/quote/VHT.US.md) - [MCHI.US](https://longbridge.com/zh-HK/quote/MCHI.US.md) - [03184.HK](https://longbridge.com/zh-HK/quote/03184.HK.md) - [512290.CN](https://longbridge.com/zh-HK/quote/512290.CN.md) - [EDIV.US](https://longbridge.com/zh-HK/quote/EDIV.US.md) - [02836.HK](https://longbridge.com/zh-HK/quote/02836.HK.md) - [03404.HK](https://longbridge.com/zh-HK/quote/03404.HK.md) - [510660.CN](https://longbridge.com/zh-HK/quote/510660.CN.md) - [EMXC.US](https://longbridge.com/zh-HK/quote/EMXC.US.md) - [VWO.US](https://longbridge.com/zh-HK/quote/VWO.US.md) - [BIS.US](https://longbridge.com/zh-HK/quote/BIS.US.md) - [FEMX.AU](https://longbridge.com/zh-HK/quote/FEMX.AU.md) - [588250.CN](https://longbridge.com/zh-HK/quote/588250.CN.md) - [516500.CN](https://longbridge.com/zh-HK/quote/516500.CN.md) - [159102.CN](https://longbridge.com/zh-HK/quote/159102.CN.md) - [159859.CN](https://longbridge.com/zh-HK/quote/159859.CN.md) - [GMF.US](https://longbridge.com/zh-HK/quote/GMF.US.md) - [IHE.US](https://longbridge.com/zh-HK/quote/IHE.US.md) - [BIB.US](https://longbridge.com/zh-HK/quote/BIB.US.md) - [159892.CN](https://longbridge.com/zh-HK/quote/159892.CN.md) - [EEM.US](https://longbridge.com/zh-HK/quote/EEM.US.md) - [XLV.US](https://longbridge.com/zh-HK/quote/XLV.US.md) - [159506.CN](https://longbridge.com/zh-HK/quote/159506.CN.md) - [DEM.US](https://longbridge.com/zh-HK/quote/DEM.US.md) - [512010.CN](https://longbridge.com/zh-HK/quote/512010.CN.md) - [DFEV.US](https://longbridge.com/zh-HK/quote/DFEV.US.md) - [IEMG.US](https://longbridge.com/zh-HK/quote/IEMG.US.md) - [PBE.US](https://longbridge.com/zh-HK/quote/PBE.US.md) - [ARKG.US](https://longbridge.com/zh-HK/quote/ARKG.US.md) - [520880.CN](https://longbridge.com/zh-HK/quote/520880.CN.md) - [LABU.US](https://longbridge.com/zh-HK/quote/LABU.US.md) - [159849.CN](https://longbridge.com/zh-HK/quote/159849.CN.md) - [IXJ.AU](https://longbridge.com/zh-HK/quote/IXJ.AU.md) - [SCHE.US](https://longbridge.com/zh-HK/quote/SCHE.US.md) - [159837.CN](https://longbridge.com/zh-HK/quote/159837.CN.md) - [520690.CN](https://longbridge.com/zh-HK/quote/520690.CN.md) - [SBIO.US](https://longbridge.com/zh-HK/quote/SBIO.US.md) - [159992.CN](https://longbridge.com/zh-HK/quote/159992.CN.md) - [516930.CN](https://longbridge.com/zh-HK/quote/516930.CN.md) - [83404.HK](https://longbridge.com/zh-HK/quote/83404.HK.md) - [AVES.US](https://longbridge.com/zh-HK/quote/AVES.US.md) - [513060.CN](https://longbridge.com/zh-HK/quote/513060.CN.md) - [FBT.US](https://longbridge.com/zh-HK/quote/FBT.US.md) - [IXJ.US](https://longbridge.com/zh-HK/quote/IXJ.US.md) - [513700.CN](https://longbridge.com/zh-HK/quote/513700.CN.md) - [IBB.US](https://longbridge.com/zh-HK/quote/IBB.US.md) - [XBI.US](https://longbridge.com/zh-HK/quote/XBI.US.md) - [159316.CN](https://longbridge.com/zh-HK/quote/159316.CN.md) - [EVLU.US](https://longbridge.com/zh-HK/quote/EVLU.US.md) - [LABD.US](https://longbridge.com/zh-HK/quote/LABD.US.md) - [EEMA.US](https://longbridge.com/zh-HK/quote/EEMA.US.md) - [IBBQ.US](https://longbridge.com/zh-HK/quote/IBBQ.US.md) - [513120.CN](https://longbridge.com/zh-HK/quote/513120.CN.md) - [EMGF.US](https://longbridge.com/zh-HK/quote/EMGF.US.md) - [SPEM.US](https://longbridge.com/zh-HK/quote/SPEM.US.md) - [09404.HK](https://longbridge.com/zh-HK/quote/09404.HK.md) ## 相關資訊與研究 - [華爾街看好健康保險板塊，分析師上調多家公司評級](https://longbridge.com/zh-HK/news/287081375.md) - [川普投資組合神操作？Medicare 政策翻盤前 精準大買聯合健康](https://longbridge.com/zh-HK/news/287039034.md) - [巨生醫獲 SelectUSA 醫療科技組金牌 啟動美國 A 輪募資目標 1000 萬美元](https://longbridge.com/zh-HK/news/286905054.md) - [藥捷安康 18% 配股籌近 1.6 億](https://longbridge.com/zh-HK/news/286831352.md) - [石藥集團抗癌藥 SYH2095 片獲準內地開展臨牀試驗](https://longbridge.com/zh-HK/news/286832616.md)